Tanya Trewick Ryans
Family · Newark, DENPI 1689056343
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 39 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 9.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,443, more than ten times the $68 reported in 2021.
Across 39 payments — averaging $87.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$320
- E.r. Squibb & Sons, L.L.C.$261
- Teva Pharmaceuticals USA, Inc.$258
- Boehringer Ingelheim$238
- Dexcom, Inc.$222
- Neurocrine Biosciences, Inc.$179
- plus $2K from 18 others
What the payments were for
- Food & beverage$3,410100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 3 | $320 |
| E.r. Squibb & Sons, L.L.C. | 3 | $261 |
| Teva Pharmaceuticals USA, Inc. | 4 | $258 |
| Boehringer Ingelheim | 2 | $238 |
| Dexcom, Inc. | 2 | $222 |
| Neurocrine Biosciences, Inc. | 3 | $179 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $176 |
| Vanda Pharmaceuticals Inc. | 2 | $136 |
| Paratek Pharmaceuticals, Inc. | 1 | $125 |
| Gilead | 1 | $125 |
| Otsuka America Pharmaceutical, Inc. | 1 | $125 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $125 |
| Bayer | 1 | $120 |
| Insulet Corporation | 1 | $113 |
| Phathom Pharmaceuticals, Inc. | 1 | $101 |
| Regeneron Healthcare Solutions, Inc. | 1 | $101 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $100 |
| Novo Nordisk | 1 | $100 |
| Lilly USA, LLC | 1 | $99 |
| AstraZeneca | 1 | $95 |
| GSK | 1 | $88 |
| Biogen | 1 | $83 |
| Mallinckrodt Hospital Products Inc. | 1 | $79 |
| AbbVie | 2 | $41 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Austedo XR$223
- CAPLYTA$128
- INGREZZA$128
- NUZYRA$125
- Tavneos$125
- Descovy$125
- Fanapt$125
- LUMRYZ$125
- REXULTI$125
- Kerendia$120
- DEXCOM G7 GSS (161)$116
- DEXCOM STELO GLUCOSE BIOSENSOR$116
- Omnipod$113
- DEXCOM G6 TRANSMITTER$107
- VOQUEZNA$101
- DUPIXENT$101
- LifeVest$100
How this compares
$3,410 in reported general payments places this provider in the 85th percentile of 523 family providers in Delaware.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 43 | $38,839 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $35,833 |
| TrulicityDulaglutide | 34 | $31,192 |
| OzempicSemaglutide | 14 | $21,770 |
| EliquisApixaban | 26 | $14,551 |
| RestasisCyclosporine | 13 | $11,065 |
| DuleraMometasone/Formoterol | 11 | $6,460 |
| LinzessLinaclotide | 11 | $5,949 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,707 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $2,714 |
| Atorvastatin Calcium | 209 | $1,975 |
| Fluticasone Propionate | 108 | $1,860 |
| Omeprazole | 119 | $1,530 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $1,431 |
| Diclofenac Sodium | 36 | $1,305 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $88 | $40,54052 claims |
| Boehringer IngelheimJardiance | $238 | $38,83943 claims |
| Lilly USA, LLCTrulicity | $99 | $31,19234 claims |
| Novo NordiskOzempic | $100 | $21,77014 claims |
| AbbVieRestasis, Linzess | $41 | $17,01424 claims |
| AstraZenecaSymbicort | $95 | $2,71416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 523 family providers in Delaware.
Other family in Newark
- Kathy GallagherNewark$53K
- Jodie DelesioNewark$50K
- Melanie HiesterNewark$9K
- Samatha GrayNewark$9K
- Byron MayNewark$8K
- Clare MatisNewark$8K
- Christine MazzolaNewark$7K
- Kelsey FrybergerNewark$7K
- Colleen AllenNewark$7K
- Mallory KowalskiNewark$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.